Staff Directory

Filter By Surname
Filter By Position
Filter By Keyword
Filter By Cancer Type
Search
Email
Dr Jane Sosabowski
Reader in Preclinical Molecular Imaging

My main interests are in radiopharmaceutical development and the use of pre-clinical molecular imaging in drug development, especially biopharmaceuticals. The lab has a long-standing interest in imaging CCK-2 and GRP receptors which are overexpressed in a number of tumour types.
Email
Dr Eva Crosas-Molist

In 2015 I was awarded a research associate position funded by Cancer Research UK to join Dr Sanz-Moreno for my postdoc, where I develop my research studying the crosstalk between the cytoskeleton and mitochondria during tumour progression and invasion.
Email
Dr Jesus Gomez Escudero

I am involved in some projects that are focused in the stroma components of a tumour, particularly the endothelial vessels, and its potential role in some key processes including chemotherapy or metastasis.
Email
Dr Julie Foster

My areas of interest are imaging biochemical processes such as metabolism/proliferation (microPET), and the use of in vivo preclinical imaging in a range of applications.
Email
Dr Florian Laforets

My research in Prof Balkwill’s group focuses on imaging tumour-associated macrophages and other immune cells in live ex vivo tumour slices, in order to assess their behaviour and the impact of immunotherapies on the live tumour microenvironment.
Email
Dr Oscar Maiques

My research will focus on studying Myosin II function during melanoma progression and its cross-talk with inflammatory and immune responses.
Email
Dr Marie Nollet

Our group has shown that internalised c-Met traffics through endomembranes positive for LC3B and Beclin1. Furthermore, c-Met sustains signalling from Autophagy Related Endomembranes, ARE. We hypothesised therefore that the AREs supporting c-Met trafficking and signalling belong to a novel non-canonical pathway.
Email
Dr Laura Wisniewski

My project looks at the modelling of cancer for improved therapy development. I am carrying out in vivo cancer experiments, with and without modifications of the tumour microenvironment, to examine effects of such treatments on anti-cancer therapy efficacy.